About Robert Ruffolo
Robert Ruffolo is a director at Elicio Therapeutics.
Form D filings name Robert Ruffolo as a director at Lb Pharmaceuticals.
Robert Ruffolo reports to the SEC as a director or officer of 6 public companies, including LB Pharmaceuticals (LBRX), Sigilon Therapeutics (SGTX) and Aridis Pharmaceuticals (ARDS).
Robert Ruffolo first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Robert Ruffolo in the role, so the role may have started earlier or lasted longer.
EI
Elicio Therapeutics, Inc.
Director
2023 – 2026 · Public company (ELTX)
SI
Sigilon Therapeutics, Inc.
Director
2020 – 2023 · Public company (SGTX)
AI
Aridis Pharmaceuticals, Inc.
Director
2018 – 2022 · Public company (ARDS)
CI
CervoMed Inc.
Director
2017 – 2018 · Public company (CRVO)
WY
Wyeth
Sr. VP & Pres., Wyeth Research
2006 – 2008 · Public company (WYE)
Key Colleagues at Startups
The people Robert Ruffolo works with at each company, as listed on that company's latest Form D.
LB Pharmaceuticals Inc. · Form D/A, Jan 10, 2024
RJ
Rajul Jain
Director
RN
Ran Nussbaum
Director
ZP
Zachary Prensky
Chief Executive Officer and director
AV
Andrew Vaino
Executive officer
AE
Anna Eramo
Executive officer
MP
Marc Panoff
Executive officer
RL
Rebecca Luse
Director
CY
Chen Yu
Director